背景：研究表明，许多外泌体microRNAs（miRNAs）可以用作肺癌的非侵入性生物标志物，但其诊断和预后价值尚需进一步明确.
方法：我们在WebofScience上进行了系统的文献检索，PubMed,和ScienceDirect数据库，获得相关文章并提取数据，用统计学方法和统计软件综合评价外泌体miRNAs在肺癌中的诊断和预后价值。
背景：PROSPEROCRD42023447398。
结果：在诊断方面，据报道，两种外泌体miRNA（miR-486-5p和miR-451a）在肺癌患者中频率最高，两者均有较好的诊断价值。与对照组相比,miR-486-5p和miR-451a的合并敏感性分别为0.80（95％CI：0.73-0.86）和0.76（95％CI：0.60-0.87），特异性：0.93（95%CI：0.63-0.99）和0.85（95%CI：0.72-0.92），和AUC：0.85（95%CI：0.81-0.88）和0.88（95%CI：0.84-0.90），对于各自的miRNA。为了预后，在外泌体miRNAs异常表达的肺癌患者中，miR-1290与PFS结果相关；miR-382、miR-1246、miR-23b-3p，miR-21-5p,miR-10b-5p与OS结局相关;miR-21和miR-4257与DFS结局相关;miR-125a-3p和miR-625-5p与PFS和OS结局相关;miR-216b和miR-451a与OS和DFS结局相关。
结论：外泌体miRNAs是肺癌患者有价值的生物标志物。外泌体miR-486-5p和miR-451a可作为新的肺癌诊断生物标志物。异常调节的外泌体miRNA可以作为肺癌患者生存结果的指标。
BACKGROUND: Studies have shown that many exosomal microRNAs (miRNAs) can be used as non-invasive biomarkers of lung cancer, but their diagnostic and prognostic values need to be further clarified.
METHODS: We conducted a systematic literature search in Web of Science, PubMed, and ScienceDirect databases, obtained relevant articles and extracted data, and used statistical methods and statistical software to comprehensively evaluate the diagnostic and prognostic value of exosomal miRNAs in lung cancer.
BACKGROUND: PROSPERO CRD42023447398.
RESULTS: In terms of diagnosis, two exosomal miRNAs (miR-486-5p and miR-451a) were reported with the highest frequency in lung cancer patients, both of which had good diagnostic value. Compared with the control group, the pooled sensitivities of miR-486-5p and miR-451a were 0.80 (95% CI: 0.73-0.86) and 0.76 (95% CI: 0.60-0.87), specificities: 0.93 (95% CI: 0.63-0.99) and 0.85 (95% CI: 0.72-0.92), and AUCs: 0.85 (95% CI: 0.81-0.88) and 0.88 (95% CI: 0.84-0.90), for the respective miRNAs. For prognosis, in lung cancer patients with abnormally expressed exosomal miRNAs, miR-1290 was associated with PFS outcome; miR-382, miR-1246, miR-23b-3p, miR-21-5p, and miR-10b-5p were associated with OS outcome; miR-21 and miR-4257 were associated with DFS outcome; miR-125a-3p and miR-625-5p were associated with PFS and OS outcomes; miR-216b and miR-451a were associated with OS and DFS outcomes.
CONCLUSIONS: Exosomal miRNAs are valuable biomarkers in lung cancer patients. Exosomal miR-486-5p and miR-451a can be used as new diagnostic biomarkers for lung cancer. Dysregulated exosomal miRNAs could serve as indicators of survival outcomes in lung cancer patients.
